CTLA4 and colitis: Eight out of 21 (38.1%) ICI-induced colitis patients treated with PD-1/PD-L1 inhibitor monotherapy were positive for the autoantibodies, while all five ICI-induced colitis patients treated with combination of CTLA-4 and PD-1 inhibitors were negative for the autoantibodies (Table 1).